The role of personalized medicine in metastatic colorectal cancer: an evolving landscape
SY Moorcraft, EC Smyth… - Therapeutic advances …, 2013 - journals.sagepub.com
Advances in the treatment of metastatic colorectal cancer have led to an improvement in
survival from 12 months with fluorouracil monotherapy to approximately 2 years. This is …
survival from 12 months with fluorouracil monotherapy to approximately 2 years. This is …
[PDF][PDF] The role of personalized medicine in metastatic colorectal cancer: an evolving landscape
SY Moorcraft, EC Smyth, D Cunningham - 2013 - Citeseer
Advances in the treatment of metastatic colorectal cancer have led to an improvement in
survival from 12 months with fluorouracil monotherapy to approximately 2 years. This is …
survival from 12 months with fluorouracil monotherapy to approximately 2 years. This is …
The role of personalized medicine in metastatic colorectal cancer: an evolving landscape.
SY Moorcraft, EC Smyth… - Therapeutic Advances in …, 2013 - europepmc.org
Advances in the treatment of metastatic colorectal cancer have led to an improvement in
survival from 12 months with fluorouracil monotherapy to approximately 2 years. This is …
survival from 12 months with fluorouracil monotherapy to approximately 2 years. This is …
The role of personalized medicine in metastatic colorectal cancer: an evolving landscape
SY Moorcraft, EC Smyth… - Therapeutic advances …, 2013 - pubmed.ncbi.nlm.nih.gov
Advances in the treatment of metastatic colorectal cancer have led to an improvement in
survival from 12 months with fluorouracil monotherapy to approximately 2 years. This is …
survival from 12 months with fluorouracil monotherapy to approximately 2 years. This is …
[PDF][PDF] The role of personalized medicine in metastatic colorectal cancer: an evolving landscape
SY Moorcraft, EC Smyth, D Cunningham - 2013 - researchgate.net
Advances in the treatment of metastatic colorectal cancer have led to an improvement in
survival from 12 months with fluorouracil monotherapy to approximately 2 years. This is …
survival from 12 months with fluorouracil monotherapy to approximately 2 years. This is …
The role of personalized medicine in metastatic colorectal cancer: an evolving landscape.
SY Moorcraft, EC Smyth… - Therapeutic Advances …, 2013 - search.ebscohost.com
Advances in the treatment of metastatic colorectal cancer have led to an improvement in
survival from 12 months with fluorouracil monotherapy to approximately 2 years. This is …
survival from 12 months with fluorouracil monotherapy to approximately 2 years. This is …
[HTML][HTML] The role of personalized medicine in metastatic colorectal cancer: an evolving landscape
SY Moorcraft, EC Smyth… - Therapeutic Advances in …, 2013 - ncbi.nlm.nih.gov
Advances in the treatment of metastatic colorectal cancer have led to an improvement in
survival from 12 months with fluorouracil monotherapy to approximately 2 years. This is …
survival from 12 months with fluorouracil monotherapy to approximately 2 years. This is …
[PDF][PDF] The role of personalized medicine in metastatic colorectal cancer: an evolving landscape
SY Moorcraft, EC Smyth, D Cunningham - 2013 - researchgate.net
Advances in the treatment of metastatic colorectal cancer have led to an improvement in
survival from 12 months with fluorouracil monotherapy to approximately 2 years. This is …
survival from 12 months with fluorouracil monotherapy to approximately 2 years. This is …
The role of personalized medicine in metastatic colorectal cancer: an evolving landscape.
SY Moorcraft, EC Smyth… - Therapeutic Advances in …, 2013 - europepmc.org
Advances in the treatment of metastatic colorectal cancer have led to an improvement in
survival from 12 months with fluorouracil monotherapy to approximately 2 years. This is …
survival from 12 months with fluorouracil monotherapy to approximately 2 years. This is …